Handelsbanken Fonder AB Has $1.11 Million Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Handelsbanken Fonder AB raised its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 19.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,300 shares of the company’s stock after purchasing an additional 2,000 shares during the period. Handelsbanken Fonder AB’s holdings in Axsome Therapeutics were worth $1,105,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Axsome Therapeutics by 1.2% in the first quarter. Vanguard Group Inc. now owns 3,740,278 shares of the company’s stock valued at $298,474,000 after buying an additional 43,512 shares during the period. Perceptive Advisors LLC lifted its position in shares of Axsome Therapeutics by 115.5% during the 4th quarter. Perceptive Advisors LLC now owns 1,038,019 shares of the company’s stock valued at $82,616,000 after acquiring an additional 556,370 shares during the period. Millennium Management LLC lifted its position in shares of Axsome Therapeutics by 1.4% during the 2nd quarter. Millennium Management LLC now owns 739,819 shares of the company’s stock valued at $59,555,000 after acquiring an additional 10,401 shares during the period. Bellevue Group AG grew its holdings in shares of Axsome Therapeutics by 7.9% during the 1st quarter. Bellevue Group AG now owns 685,476 shares of the company’s stock worth $54,701,000 after purchasing an additional 50,104 shares in the last quarter. Finally, Hood River Capital Management LLC increased its position in shares of Axsome Therapeutics by 5.4% in the second quarter. Hood River Capital Management LLC now owns 549,066 shares of the company’s stock worth $44,200,000 after purchasing an additional 28,316 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

Insider Transactions at Axsome Therapeutics

In related news, COO Mark L. Jacobson sold 47,739 shares of the business’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $84.26, for a total value of $4,022,488.14. Following the sale, the chief operating officer now owns 5,783 shares of the company’s stock, valued at $487,275.58. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Axsome Therapeutics news, Director Mark E. Saad sold 11,016 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the completion of the transaction, the director now owns 10,002 shares in the company, valued at approximately $913,282.62. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Mark L. Jacobson sold 47,739 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $84.26, for a total transaction of $4,022,488.14. Following the completion of the transaction, the chief operating officer now owns 5,783 shares in the company, valued at $487,275.58. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 22.40% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on AXSM. UBS Group reduced their price objective on shares of Axsome Therapeutics from $107.00 to $105.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Bank of America upgraded shares of Axsome Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $95.00 to $106.00 in a research report on Tuesday, August 6th. Cantor Fitzgerald restated an “overweight” rating and set a $107.00 price objective on shares of Axsome Therapeutics in a research report on Monday, September 16th. HC Wainwright restated a “buy” rating and set a $180.00 target price on shares of Axsome Therapeutics in a research note on Thursday, September 5th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $130.00 price target on shares of Axsome Therapeutics in a research note on Thursday, September 5th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $124.64.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $87.56 on Friday. The firm has a market capitalization of $4.16 billion, a price-to-earnings ratio of -13.45 and a beta of 1.26. The company has a current ratio of 2.48, a quick ratio of 2.40 and a debt-to-equity ratio of 1.77. The business’s 50-day moving average price is $88.96 and its 200-day moving average price is $81.05. Axsome Therapeutics, Inc. has a 12 month low of $55.02 and a 12 month high of $98.40.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, August 5th. The company reported ($1.24) EPS for the quarter, topping the consensus estimate of ($1.30) by $0.06. Axsome Therapeutics had a negative net margin of 105.85% and a negative return on equity of 117.46%. The business had revenue of $87.17 million for the quarter, compared to the consensus estimate of $84.53 million. Equities research analysts forecast that Axsome Therapeutics, Inc. will post -4.73 EPS for the current year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.